Julia Pena-Asensio
Overview
Explore the profile of Julia Pena-Asensio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pena-Asensio J, Calvo-Sanchez H, Miquel-Plaza J, Sanz-de-Villalobos E, Gonzalez-Praetorius A, Delgado-Fernandez A, et al.
Front Immunol
. 2024 Mar;
15:1352929.
PMID: 38545116
Background: HBe-antigen(Ag)-negative chronic hepatitis B virus (HBV) infection is characterized by little liver fibrosis progression and vigorous HBV-multispecific CD8 T-cell response. Aims: To assess whether HBsAg level could discriminate different...
2.
Pena-Asensio J, Calvo-Sanchez H, Miquel J, Sanz-de-Villalobos E, Gonzalez-Praetorius A, Torralba M, et al.
iScience
. 2023 Dec;
27(1):108666.
PMID: 38155778
A rebalance between energy supply and demand in HBV-specific-CD8 activated progenitor (AP) cells could restore the functionality of proliferative progeny (PP) in e-antigen(Ag)-negative chronic hepatitis B (CHBe(-)). We observed that...
3.
Torralba M, Rodriguez G, Gonzalez Gasca F, Cuadra F, Barbera J, Geijo P, et al.
Ann Pharmacother
. 2023 May;
58(2):140-147.
PMID: 37131300
Background: The evaluation of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in clinical trials has shown high rates of virological suppression but information about its use in real-life settings is scarce....
4.
Pena-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, Gonzalez-Praetorius A, Torralba M, et al.
Aliment Pharmacol Ther
. 2022 Sep;
56(8):1312-1313.
PMID: 36168258
No abstract available.
5.
Calvo Sanchez H, Pena-Asensio J, Larrubia Marfil J
Rev Esp Enferm Dig
. 2022 Jul;
114(8):441-444.
PMID: 35866227
This editorial discusses current challenges in treatment stop in e-antigen-negative chronic hepatitis B, with attention to immunologic and virologic markers associated with functional cure, new therapeutic options for those cases...
6.
Pena-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, Gonzalez-Praetorius A, Torralba M, et al.
Aliment Pharmacol Ther
. 2022 Feb;
55(12):1545-1559.
PMID: 35224746
Background: Hepatitis B virus (HBV)-specific CD8 cell response restoration during nucleos(t)ide analogue (NUC) treatment could lead to off-treatment HBV control in e-antigen-negative chronic hepatitis B (CHBe(-)). Aim: To predict this...
7.
Pena-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia J
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33923463
Thirty to fifty percent of hepatocellular carcinomas (HCC) display an immune class genetic signature. In this type of tumor, HCC-specific CD8 T cells carry out a key role in HCC...
8.
Pena-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia J
Cells
. 2021 Apr;
10(3).
PMID: 33802622
Hepatitis C virus (HCV)-specific CD8 T cell response is essential in natural HCV infection control, but it becomes exhausted during persistent infection. Nowadays, chronic HCV infection can be resolved by...
9.
Pena-Asensio J, Sanz-de-Villalobos E, Miquel J, Larrubia J
World J Hepatol
. 2020 Nov;
12(10):754-765.
PMID: 33200014
Hepatitis C virus (HCV) infection is an excellent immunological model for understanding the mechanisms developed by non-cytopathic viruses and tumors to evade the adaptative immune response. The antigen-specific cytotoxic T...
10.
Moreno-Cubero E, Sanchez Del Arco R, Pena-Asensio J, de Villalobos E, Miquel J, Larrubia J
World J Gastroenterol
. 2018 May;
24(17):1825-1838.
PMID: 29740199
Chronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete...